- Aurion Biotech Appoints Donald Munoz as Chief Financial Officer
- Aurion Biotech Announces Positive Topline Data for Phase 1/2 Clinical Trial of AURN001, an Allogeneic Cell Therapy Product Candidate for the Treatment of Corneal Edema Secondary to Corneal Endothelial Dysfunction
- Aurion Biotech Launches Vyznova® in Japan for the Treatment of Bullous Keratopathy of the Cornea

Millions of People Suffer from Sight-Threatening Corneal Endothelial Diseases
Our Cell Therapy Has the Potential to
Restore Their Vision

Company recognized for innovations in clinically validated cell therapy for corneal endothelial dystrophies

Get to know us.
We are a clinical-stage biotech company. We aim to restore vision to all who need it by developing a platform of innovative, accessible, and effective advanced therapies. Our first candidate is a patented cell therapy treatment for corneal endothelial disease.
Latest News
-
Aurion Biotech Appoints Donald Munoz as Chief Financial Officer
Read More -
Aurion Biotech Announces Positive Topline Data for Phase 1/2 Clinical Trial of AURN001, an Allogeneic Cell Therapy Product Candidate for the Treatment of Corneal Edema Secondary to Corneal Endothelial Dysfunction
Read More -
Aurion Biotech Launches Vyznova® in Japan for the Treatment of Bullous Keratopathy of the Cornea
Read More